RecruitingNot ApplicableNCT07274917

Stereotactic Radiotherapy Treatment for Treatment-resistant Depression

The Efficacy and Safety of Stereotactic Radiotherapy for Treatment-Resistant Depression: An Open-Label Exploratory Study

Sponsor

Capital Medical University

Enrollment

9 participants

Start Date

Jan 26, 2026

Study Type

INTERVENTIONAL

Conditions

Treatment Resistant Depression Depressive Disorder

Summary

This study is an clinical trial aimed at evaluating the effectiveness and safety of stereotactic radiotherapy for treatment-resistant depression

Eligibility

Min Age: 18 YearsMax Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called ZAP-X for people with depressive disorder and treatment resistant depression. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 50 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEZAP-X

The individualized bilateral sgACC template will be imported into the ZAP-X treatment planning system. For left and right sgACC targets, the treatment plan will be automatically generated with the following set-up. The treatment will be carried out on two consecutive days.